基于CYP3A4和CYP2C19酶活性探究伏立康唑与COVID-19潜在抗病毒药物间的相互作用

Drug-drug interaction between voriconazole and potential anti-2019-nCoV candidates based on the CYP3A4 and CYP2C19 enzyme activity

随着新型冠状病毒肺炎(COVID-19)在全球持续蔓延,尤其是重症和危重症患者病毒感染后常合并真菌感染并可能合并使用多种治疗药物。作为广谱抗真菌药物,伏立康唑是治疗侵袭性真菌感染的常用药物之一。由于其药物代谢酶CYP2C19和CYP3A4存在基因多态性,当与这两种酶的底物、诱导剂或抑制剂联合应用时,药物相互作用可能会影响药物治疗的疗效并诱发不良反应,因此探讨CYP2C19和CYP3A4代谢酶基因多态性与CYP2C19潜在抗病毒治疗药物相互作用具有一定的临床意义。

With the ongoing spread of COVID-19 worldwide,fungal infections in patients with severe COVID-19 are common and need multi-medications treatment.As a broad-spectrum antifungal agent,voriconazole is the substrate of CYP3A4 and CYP2C19 and strong inhibitor.Extensive drug-drug interactions between voriconazole and concomitant agents may interfere the therapeutic efficacy and induce serious adverse effects.For individuals with COVID-19 and invasive fungal co-infection,it’s imperative to explore cytochrome P450 polymorphism and potential drug-drug interactions.